{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:51:37Z","timestamp":1790470297495,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":917,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1093\/annonc\/mdx040","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T19:08:46Z","timestamp":1492715326000},"page":"1137-1144","source":"Crossref","is-referenced-by-count":93,"title":["Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study"],"prefix":"10.1016","volume":"28","author":[{"given":"B.","family":"Dr\u00e9no","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.O.","family":"Koralek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.F.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx040_bb0010","unstructured":"ZELBORAF (vemurafenib) Tablets, for Oral Use. South San Francisco, CA: Genentech USA, Inc. 2015."},{"key":"10.1093\/annonc\/mdx040_bb0015","unstructured":"COTELLIC (cobimetinib) Tablets, for Oral Use. South San Francisco, CA: Genentech USA, Inc. 2015."},{"key":"10.1093\/annonc\/mdx040_bb0020","unstructured":"Cotellic 20mg Film-coated Tablets. Welwyn Garden City, UK: Roche Registration Limited 2016."},{"key":"10.1093\/annonc\/mdx040_bb0025","unstructured":"Zelboraf 240mg Film-coated Tablets. Welwyn Garden City, UK: Roche Registration Limited 2016."},{"key":"10.1093\/annonc\/mdx040_bb0030","unstructured":"Mekinist 0.5mg Film-coated Tablets. Research Triangle Park, NC: GlaxoSmithKline 2015."},{"key":"10.1093\/annonc\/mdx040_bb0035","unstructured":"TAFINLAR (dabrafenib) Capsules for Oral Use. Research Triangle Park, NC: GlaxoSmithKline 2015."},{"key":"10.1093\/annonc\/mdx040_bb0040","unstructured":"Mekinist 0.5mg Film-coated Tablets. Camberley, UK: Novartis Europharm Limited 2016."},{"key":"10.1093\/annonc\/mdx040_bb0045","unstructured":"Tafinlar 50mg Hard Capsules. Camberley, UK: Novartis Europharm Limited 2015."},{"key":"10.1093\/annonc\/mdx040_bb0050","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Overall survival with cobimetinib combined with vemurafenib in advanced BRAFV600-mutated melanoma: updated efficacy results from the phase 3, randomised coBRIM study","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx040_bb0055","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med 2014;"},{"key":"10.1093\/annonc\/mdx040_bb0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx040_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdx040_bb0070","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med 2014;"},{"key":"10.1093\/annonc\/mdx040_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9007","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment","volume":"33","author":"Sullivan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx040_bb0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdu529","article-title":"Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial","volume":"26","author":"Menzies","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx040_bb0085","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (London)"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/5\/1137\/13942839\/mdx040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T19:00:46Z","timestamp":1658948446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0923753419320162"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx040","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}